The roster of fine former Merckers, alone, makes it a likely three bagger. But it had, since about 2021, a formidable bolus of bio-oncology IP assets in the pipe, already -- on its own. Here's the latest (and a bit):
. . .Merck is set to acquire approximately $30M worth of shares in Eikon Therapeutics, which is expected to grant it nearly a 10% stake, thereby enhancing Merck's positioning in the cancer biotech sector and increasing its market competitiveness.
Eikon Therapeutics filed for its U.S. IPO this week, seeking a valuation of up to $908M, which has attracted interest from both existing and new investors, indicating strong market confidence in its oncology pipeline.
Eikon is led by Roger Perlmutter, a former president of Merck Research Laboratories, along with several other ex-top executives from Merck, which may provide a robust foundation for Eikon's success in the competitive biotech landscape. . . .
With Kenneth C. Frazier on the board, this likely is a. . . "cannot miss" bet. Smile -- everyone knows I'm a fan boy, there. Out.
नमस्ते
No comments:
Post a Comment